Neoadjuvant ddMVAC (bladder) & Nivo + Chemo (NSCLC)
from OncoPharm Hosted by John Bossaer
Results from VESPER are now published, so we revisit neoadjuvant ddMVAC and its place as SOC in bladder cancer. Nivolumab nets a new approval with chemo for neoadjuvant treatment of NSCLC. A new CAR-T product is approved for multiple myeloma.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 17 minutes long.
When was this OncoPharm episode published?
This episode was published on March 10, 2022.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.